TY - JOUR
T1 - Nutraceutical and dietary resources for breast cancer prevention – Highlighting strategies for suppressing breast aromatase expression
AU - Iloki Assanga, Simon Bernard
AU - Lewis Luján, Lidianys María
AU - McCarty, Mark F.
AU - DiNicolantonio, James J.
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/3
Y1 - 2023/3
N2 - Background: Visceral obesity and the metabolic syndrome that often accompanies it are robust and well-established risk factors for postmenopausal breast cancer. This increased risk is thought to be mediated, in large part, by increased aromatase expression in the breast. stromal adipocytes and in mammary epithelium; this results in a high local concentration of estrogen capable of supporting the cancerous transformation of estrogen receptor-positive (ER+) epithelial cells. Aromatase, a member of the cytochrome 450 family, is expressed in the endoplasmic reticulum. After menopause, it converts androgens produced within the adrenal cortex (androstenedione and testosterone) into estrogens (estrone and estradiol, respectively. Therefore, the main objective of this narrative article is to review dietary and nutraceutical remedies for the prevention of menopause. Breast cancer: leading strategies to suppress breast aromatase Methods: The research articles to carry out this work were focused based on many searches and reviews in the following databases: Google Scholar, MDPI, PubMed, ScienceDirect and using the following keywords and combined synonyms: (“nutraceuticals” or “supplements” or “aromatase inhibitors” or “aromatase” or "antioxidants”) AND (“breast cancer” or “vascular function” or “inflammation”). The keywords were also searched in the references of the original articles included in this study Conclusion: A number of nutraceutical, dietary, and lifestyle measures hold promise for breast cancer prevention and may be considered practical options by women seeking to minimize their risk. for this cancer, particularly as these measures appear to have few downsides and are likely to work in other ways to promote health.
AB - Background: Visceral obesity and the metabolic syndrome that often accompanies it are robust and well-established risk factors for postmenopausal breast cancer. This increased risk is thought to be mediated, in large part, by increased aromatase expression in the breast. stromal adipocytes and in mammary epithelium; this results in a high local concentration of estrogen capable of supporting the cancerous transformation of estrogen receptor-positive (ER+) epithelial cells. Aromatase, a member of the cytochrome 450 family, is expressed in the endoplasmic reticulum. After menopause, it converts androgens produced within the adrenal cortex (androstenedione and testosterone) into estrogens (estrone and estradiol, respectively. Therefore, the main objective of this narrative article is to review dietary and nutraceutical remedies for the prevention of menopause. Breast cancer: leading strategies to suppress breast aromatase Methods: The research articles to carry out this work were focused based on many searches and reviews in the following databases: Google Scholar, MDPI, PubMed, ScienceDirect and using the following keywords and combined synonyms: (“nutraceuticals” or “supplements” or “aromatase inhibitors” or “aromatase” or "antioxidants”) AND (“breast cancer” or “vascular function” or “inflammation”). The keywords were also searched in the references of the original articles included in this study Conclusion: A number of nutraceutical, dietary, and lifestyle measures hold promise for breast cancer prevention and may be considered practical options by women seeking to minimize their risk. for this cancer, particularly as these measures appear to have few downsides and are likely to work in other ways to promote health.
KW - Aromatase
KW - Long-chain omega-3
KW - Melatonin
KW - Nrf2
KW - Postmenopausal breast cancer
KW - Soy foods
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85147292010&partnerID=8YFLogxK
U2 - 10.1016/j.phanu.2022.100327
DO - 10.1016/j.phanu.2022.100327
M3 - Artículo de revisión
AN - SCOPUS:85147292010
SN - 2213-4344
VL - 23
JO - PharmaNutrition
JF - PharmaNutrition
M1 - 100327
ER -